|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Available experimental evidence suggests that galectin-3 inhibition indeed may represent a novel tool to treat heart failure.
|
24789662 |
2014 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cardiac (NT-proBNP, cTnI, sST2,Gal-3) and inflammatory (IL-6,IL-8) biomarkers were determined in plasma collected from 12 paediatric patients and 7 adult patients with HF, before and at 4 h,1,3,7,14 and 30 days after VAD implant.
|
30040920 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46).
|
30573026 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Circulating galectin-3 (Gal-3) is elevated and significantly correlates with all-cause and cardiovascular mortality in patients with heart failure.
|
30477951 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Correction to: The potential prognostic utility of salivary galectin-3 concentrations in heart failure.
|
31823039 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
CT-1 (cardiotrophin-1) and Gal-3 (galectin-3) are increased in HF and associated with myocardial fibrosis.
|
30612490 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Elevated galectin-3 has been associated with atherosclerosis and poor outcomes in patients with heart failure.
|
29229724 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Elevated plasma galectin-3 levels, a biomarker associated with myocardial fibrosis, are also associated with adverse cardiovascular events, including heart failure.
|
30721387 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications.
|
29153203 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, elevated natriuretic peptides, ST2, endothelin-1, mid-regional-pro-adrenomedullin, copeptin, and galectin-3 have all been well validated to predict death and heart failure following a MI and provide risk stratification information for heart failure.
|
28491088 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Following the recommendation of natriuretic peptides (B-type natriuretic peptide and N-terminal-proBNP), many other biomarkers have been thoroughly studied to reflect different pathophysiological processes (such as fibrosis, inflammation, myocardial injury, and remodeling) in HF and some of them (like cardiac troponins, soluble suppression of tumorigenesis-2, and galectin 3) have subsequently been recommended to aid in the diagnosis and prognostication in HF.
|
31183637 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, ROC curve analysis suggested galectin-3 as a promising biomarker for diagnosis and HF and clinical severity.
|
31514240 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, CK-MB, sST2, and Gal-3 exhibited a modest diagnostic performance for HF, with an AUC of 0.709, 0.711, and 0.777, respectively.
|
30829708 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, inhibition of galectin‑3 by intravenous tail vein injection of a galectin‑3‑targeting short hairpin RNA‑expressing vector during hypertension‑induced heart failure in Dahl hypertensive rats increased rat survival and body weight.
|
29286090 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, only Gal-3 was the independent predictor of HF development at one-year observation.
|
31687050 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, α1-antitrypsin and lectin-like oxidized low-density-lipoprotein receptor-1 seem to represent two good markers in HF and therapeutic targets, whereas galectin-3 does not.
|
31782085 |
2020 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize recent progress in research on galectin-3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
|
30372548 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased galectin-3 plasma concentration has been linked to an unfavorable outcome in patients with heart failure or atrial fibrillation (AF).
|
29118378 |
2017 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.
|
29844319 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Multivariable Cox proportional hazards models, adjusted for AF risk factors plus incident heart failure (HF) and coronary heart disease (CHD), were used to estimate hazard ratios for the association between galectin-3 and incident AF.
|
28938960 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
Myocardial biopsies obtained at an early stage of hypertrophy before apparent HF showed that expression of galectin-3 was increased specifically in the rats that later rapidly developed HF.
|
15520318 |
2004 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Myocardial biopsies obtained at an early stage of hypertrophy before apparent HF showed that expression of galectin-3 was increased specifically in the rats that later rapidly developed HF.
|
15520318 |
2004 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have additional benefit in assessment of cardiac remodeling or differentiation of HF subtypes.
|
29682806 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recent clinical studies have shown that galectin-3 is a prognostic indicator in patients with coronary heart disease and in patients with heart failure.
|
30378236 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Salivary Gal-3 concentrations were significantly higher (p < 0.05) in patients with HF who subsequently experienced the primary endpoint compared to those who did not.
|
31598750 |
2019 |